Dr. Monk Discusses the TRINOVA-1 Trial

Bradley J. Monk, MD,
Published: Wednesday, Nov 20, 2013

Bradley J. Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the TRINOVA-1 trial.

The trial, which studied trebananib plus paclitaxel versus placebo plus paclitaxel, enrolled 919 patients who had recurrent ovarian cancer who have had up to three prior lines of therapy, Monk says.

Monk says trebananib is a peptibody that binds and inactivates angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Ang1 and Ang2 are different angiogenesis pathways. This pathway is needed, Monk says, because bevacizumab and other anti-VEGF therapies have unique side effects such as hypertension, proteinuria, GI perforation, wound healing, and even central nervous system dysfunction. By targeting another pathway, physicians are hoping to eliminate those side effects.

Monk says the trial showed that trebananib plus weekly paclitaxel improved the hazard ratio for progression by .66. The combination also improved response rate and the survival data, although not yet mature, showed a hazard ratio of .86.

Bradley J. Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the TRINOVA-1 trial.

The trial, which studied trebananib plus paclitaxel versus placebo plus paclitaxel, enrolled 919 patients who had recurrent ovarian cancer who have had up to three prior lines of therapy, Monk says.

Monk says trebananib is a peptibody that binds and inactivates angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Ang1 and Ang2 are different angiogenesis pathways. This pathway is needed, Monk says, because bevacizumab and other anti-VEGF therapies have unique side effects such as hypertension, proteinuria, GI perforation, wound healing, and even central nervous system dysfunction. By targeting another pathway, physicians are hoping to eliminate those side effects.

Monk says the trial showed that trebananib plus weekly paclitaxel improved the hazard ratio for progression by .66. The combination also improved response rate and the survival data, although not yet mature, showed a hazard ratio of .86.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Community Practice Connections™: 1st Annual School of Nursing Oncology™Oct 31, 20181.5
Publication Bottom Border
Border Publication
x